FDA Approves First Drug for Advanced cSCC
Cemiplimab (Libtayo), approved for advanced cutaneous squamous cell carcinoma, is intended for those not eligible for curative surgery or radiation. (Source: CancerNetwork)
Source: CancerNetwork - October 10, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news
Increased survival in patients with metastatic NSCLC receiving treatment in academic centers
(International Association for the Study of Lung Cancer) Patients with metastatic NSCLC receiving treatment at academic centers (ACs) have an increased 2-year survival compared to patients treated at community-based centers (CCs). An overall histology-dependent survival was also noted in patients with adenocarcinoma verses squamous cell carcinoma and varied by treatment facility. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 10, 2018 Category: Cancer & Oncology Source Type: news
FDA approves Sanofi and Regeneron's skin cancer med
The imunotherapy Libtayo can treat patients with particular kinds of cutaneous squamous cell carcinoma. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 2, 2018 Category: Pharmaceuticals Source Type: news
' Transformational' Results in Squamous Cell Lung Cancer'Transformational' Results in Squamous Cell Lung Cancer
An immuno-chemotherapy combination again moves the bar forward in a difficult-to-treat subset of squamous cell lung cancer patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
FDA Approves New Treatment for Squamous Cell Carcinoma
Libtayo is the sixth FDA - approved immune checkpoint inhibitor targeting the PD - 1 pathway (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 2, 2018 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Institutional, Source Type: news
First treatment approved for common form of advanced skin cancer
The FDA has approved the first treatment for patients with metastatic cutaneous squamous cell carcinoma who are not candidates for surgery or radiation. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 1, 2018 Category: Consumer Health News Source Type: news
FDA Approves Cemiplimab, First Drug for Advanced CSCC FDA Approves Cemiplimab, First Drug for Advanced CSCC
The US Food and Drug Administration today approved cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced, unresectable CSCC.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Libtayo (cemiplimab-rwlc) for Advanced Cutaneous Squamous Cell Carcinoma
September 28, 2018 -- The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 28, 2018 Category: Drugs & Pharmacology Source Type: news
FDA approves first treatment for advanced form of the second most common skin cancer
FDA approves Libtayo (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC. (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 28, 2018 Category: American Health Source Type: news
FDA approves first treatment for advanced form of the second most common skin cancer
The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC. (Source: World Pharma News)
Source: World Pharma News - September 28, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
DNA vaccine leads to immune responses in HPV-related head and neck cancer
(University of Pennsylvania School of Medicine) A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of Pennsylvania tested the immunotherapy approach in two groups of patients with advanced head and neck squamous cell carcinoma (HNSCCa) and found 86 percent showed elevated T cell activity. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 21, 2018 Category: Cancer & Oncology Source Type: news
CRISPR screen reveals new targets in more than half of all squamous cell carcinomas
(University of Colorado Anschutz Medical Campus) Team of University of Colorado Cancer Center researchers sheds light on p63 activity in squamous cell carcinoma of the lung, providing an actionable path forward to drug development against this known cause of cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 18, 2018 Category: International Medicine & Public Health Source Type: news
Total of 43,371 New Cases of HPV-Associated Cancers in 2015
TUESDAY, Sept. 11, 2018 -- A total of 43,371 new cases of human papillomavirus (HPV)-associated cancers were reported in 2015, with oropharyngeal squamous cell carcinoma (SCC) being the most common HPV-associated cancer, according to research... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 11, 2018 Category: Pharmaceuticals Source Type: news
Study links widely used drug azathioprine to skin cancers
(University of Dundee) A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an important contributor to skin cancer development.The research, published in Nature Communications, identified a 'strong case for an association' between the drug azathioprine and the mutational signature found in cases of cutaneous squamous cell carcinoma (cSCC), a common form of skin cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 10, 2018 Category: Cancer & Oncology Source Type: news
Study links widely-used drug azathioprine to skin cancers
(University of Dundee) A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an important contributor to skin cancer development.The research, published in Nature Communications, identified a `strong case for an association' between the drug azathioprine and the mutational signature found in cases of cutaneous squamous cell carcinoma (cSCC), a common form of skin cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 10, 2018 Category: Cancer & Oncology Source Type: news
